Interim Analysis of the Randomized Phase 1b/3 Study Evaluating the Safety and Efficacy of Tazemetostat Plus Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma

被引：5

作者：

Batlevi, Connie Lee ^{[1
]}

Park, Steven I. ^{[2
]}

Nastoupil, Loretta ^{[3
]}

Phillips, Tycel ^{[4
]}

Amengual, Jennifer E. ^{[5
]}

Andorsky, David ^{[6
]}

Campbell, Philip ^{[7
]}

McKay, Pamela ^{[8
]}

Pagel, John M. ^{[9
]}

Leonard, John P. ^{[10
]}

Yang, Jay ^{[11
]}

O'Connor, Heather ^{[11
]}

Hamlett, Anthony ^{[11
]}

Adib, Deyaa ^{[11
]}

Morschhauser, Franck ^{[12
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, New York, NY USA

[2] Levine Canc Inst, Dept Hematol Oncol & Blood Disorders, Charlotte, NC USA

[3] MD Anderson Canc Ctr, Houston, TX USA

[4] Univ Michigan, Ann Arbor, MI USA

[5] Columbia Univ, Irving Med Ctr, New York, NY USA

[6] Rocky Mt Canc Ctr, Boulder, CO USA

[7] Univ Hosp Geelong, Barwon Hlth, Geelong, Vic, Australia

[8] Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland

[9] Swedish Canc Inst, Ctr Blood Disorders & Stem Cell Transplantat, Seattle, WA USA

[10] Weill Cornell Med, New York, NY USA

[11] Epizyme Inc, Cambridge, MA USA

[12] Univ Lille, CHU Lille, EA 7365 GRITA Grp Rech Formes Injectables & Tec, F-59000 Lille, France

来源：

BLOOD | 2021年 / 138卷

关键词：

D O I：

10.1182/blood-2021-148199

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

2207

引用

页数：6

共 50 条

[31] Phase 1 study of tazemetostat in Japanese patients with relapsed or refractory B-cell lymphoma
Munakata, Wataru
Shirasugi, Yukari
Tobinai, Kensei
Onizuka, Makoto
Makita, Shinichi
Suzuki, Rikio
Maruyama, Dai
Kawai, Hidetsugu
Izutsu, Koji
Nakanishi, Tadashi
Shiba, Sari
Hojo, Seichiro
Ando, Kiyoshi
CANCER SCIENCE, 2021, 112 (03) : 1123 - 1131
[32] Phase 1b/2 Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory B-Cell Lymphoma: Safety, Efficacy and Molecular Analysis
Melani, Christopher
Lakhotia, Rahul
Pittaluga, Stefania
Miljkovic, Milos D.
Phelan, James D.
Muppidi, Jagan R.
Thomas, Craig J.
Ceribelli, Michele
Tosto, Frances Anne
Portell, Craig A.
Farah, Rafic J.
Lee, Seung Tae
Juanitez, Anna Marie
Steinberg, Seth M.
Jaffe, Elaine S.
Roschewski, Mark
Staudt, Louis M.
Wilson, Wyndham H.
BLOOD, 2020, 136
[33] MAGNIFY: Phase IIIb Randomized Study of Lenalidomide Plus Rituximab (R) Followed By Lenalidomide Vs. Rituximab Maintenance in Subjects with Relapsed/Refractory Follicular, Marginal Zone, or Mantle Cell Lymphoma
Andorsky, David J.
Yacoub, Abdulraheem
Bitran, Jacob D.
Melear, Jason
Brooks, Heather D.
Foon, Kenneth A.
Rizvi, Syed
Llorente, Mary
Li, Jiahui
Sharman, Jeff P.
BLOOD, 2016, 128 (22)
[34] Phase 1/1b Study of the Efficacy and Safety of the Combination of Panobinostat plus Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma
Shah, Jatin J.
Thomas, Sheeba K.
Weber, Donna M.
Wang, Michael
Alexanian, Raymond
Qazilbash, Muzaffar H.
Bashir, Qaiser
Parmar, Simrit
Shah, Nina
Popat, Uday R.
Orlowski, Robert Z.
BLOOD, 2012, 120 (21)
[35] y Portia: A Phase 1b Study Evaluating Safety and Efficacy of Tisagenlecleucel and Pembrolizumab in Patients with Relapsed/ Refractory Diffuse Large B-Cell Lymphoma
Jaeger, Ulrich
Worel, Nina
McGuirk, Joseph P.
Riedell, Peter A.
Fleury, Isabelle
Borchmann, Peter
Chu, Jufen
Abdelhady, Ahmed M.
Forcina, Alessandra
Pacaud, Lida Bubuteishvili
Waller, Edmund K.
BLOOD, 2019, 134
[36] Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Follicular Lymphoma (CITADEL-203)
Lynch, Ryan C.
Paneesha, Shankara
Avigdor, Abraham
McKinney, Matthew S.
Wahlin, Bjorn E.
Hrom, John S.
Belada, David
Canales, Miguel
Cunningham, David
Devizzi, Liliana
Morley, Nicholas
Zheng, Fred
DeMarini, Douglas J.
Jiang, Wei
Trneny, Marek
BLOOD, 2020, 136
[37] Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients With Relapsed or Refractory Follicular Lymphoma (CITADEL-203)
Lynch, Ryan C.
Paneesha, Shankara
Avigdor, Abraham
McKinney, Matthew S.
Wahlin, Bjorn E.
Hrom, John S.
Belada, David
Canales, Miguel
Cunningham, David
Devizzi, Liliana
Morley, Nicholas
Zheng, Fred
DeMarini, Douglas J.
Jiang, Wei
Trneny, Marek
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (01) : 11 - 12
[38] Lenalidomide Plus Rituximab for Relapsed or Refractory Diffuse Large B-Cell, Follicular and Transformed Lymphoma: Final Data Analysis of a Phase 2 Trial
Wang, Yucai
Wagner-Bartak, Nicolaus
Zhou, Shouhao
Fowler, Nathan
Dela Rosa, Maria Lourdes
Zhao, Donglu
Romaguera, Jorge E.
Neelapu, Sattva S.
Hagemeister, Fredrick B.
Fanale, Michelle A.
Oki, Yasuhiro
Shah, Jatin J.
Thomoas, Sheeba K.
Hosing, Chitra M.
Zhang, Liang
Badillo, Maria
Chen, Wendy
Cai, Qingqing
Zou, Dehui
Champlin, Richard E.
Fayad, Luis E.
Lee, Hun Ju
Wang, Michael
BLOOD, 2015, 126 (23)
[39] A Phase 2, Open-Label, Multicenter Study of Tazemetostat in Combination with Rituximab for the Treatment of Relapsed or Refractory Follicular Lymphoma
Patel, Krish
Bailey, Neil
Pagel, John M.
BLOOD, 2020, 136
[40] Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study
Seymour, John F.
Ma, Shuo
Brander, Danielle M.
Choi, Michael Y.
Barrientos, Jacqueline
Davids, Matthew S.
Anderson, Mary Ann
Beaven, Anne W.
Rosen, Steven T.
Tam, Constantine S.
Prine, Betty
Agarwal, Suresh K.
Munasinghe, Wijith
Zhu, Ming
Lash, L. Leanne
Desai, Monali
Cerri, Elisa
Verdugo, Maria
Kim, Su Young
Humerickhouse, Rod A.
Gordon, Gary B.
Kipps, Thomas J.
Roberts, Andrew W.
LANCET ONCOLOGY, 2017, 18 (02): : 230 - 240

← 1 2 3 4 5 →